scholarly journals Investigation of factors related to N-terminal pro-B type natriuretic peptide levels in hemodialysis patients; a single center study

2019 ◽  
Vol 9 (1) ◽  
pp. e05-e05
Author(s):  
Farbod Bonakdar ◽  
Pegah Noorshargh ◽  
Parin Hedayati ◽  
Hamid Nasri
Keyword(s):  
Renal Disease ◽  
Lipid Profile ◽  
Natriuretic Peptide ◽  
Demographic Data ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Serum Triglyceride ◽  
Hemodialysis Patients ◽  
Stage Renal Disease ◽  
Esrd Patients

Introduction: Introduction: N-terminal pro-B type natriuretic peptide (NT-proBNP) can be used to diagnose cardiac and renal disease. The association of NT-pro BNP with demographic, clinical and biochemical factors in hemodialysis is unclear. Objectives: This study aimed to examine association of NT-pro BNP and mentioned factors in hemodialysis patients. Patients and Methods: This study was conducted on 78 end-stage renal disease (ESRD) patients under hemodialysis. Demographic data, lipid profile and electrolytes were recorded. NT-proBNP was checked simultaneously and its association with mentioned factors were assessed. Results: The average NT-pro BNP level was 890.52±700.87 pg/mL (range: 0.1-3343 pg/mL). Serum level of NT-pro BNP was statistically in association with total cholesterol (P=0.002; r=-0.348), low density lipoprotein (LDL) (P=0.09; r= -0.292), high density lipoprotein (HDL) (P=0.06; r=-0.310) and serum triglyceride (P=0.018; r=-0.269) while having a direct relationship with serum ferritin (P=0.022; r=0.274), alkaline phosphatase (ALP) (P=0.048; r=0.224) and duration of hemodialysis (P=0.005; r=0.321). Conclusion: Lipid profile and ferritin are associated with NT-pro BNP levels. This can reflect possible prognostic role of NT-proBNP among ESRD patients on hemodialysis.

scholarly journals IMPACT OF DURATION OF HEMODIALYSIS ON LIPID PROFILE IN END STAGE RENAL DISEASE PATIENTS RECEIVING HEMODIALYSIS.

2020 ◽  
Vol 27 (06) ◽  
pp. 1230-1236
Author(s):  
Sadia Rehman ◽  
Santosh Kumar ◽  
Fatima Mehboob ◽  
Fatima Rehman ◽  
Syed Hidayat Ali ◽  
...  
Keyword(s):  
Renal Disease ◽  
Lipid Profile ◽  
End Stage Renal Disease ◽  
Serum Triglyceride ◽  
Hemodialysis Patients ◽  
Maintenance Hemodialysis ◽  
Healthy Controls ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

End Stage Renal Disease (ESRD) patients receiving hemodialysis are at a higher risk of developing dyslipidemia which is undoubtedly a predisposing factor of cardiac related disease in these patients. Objectives: To assess serum lipid profile in subjects having end stage renal disease and receiving maintenance hemodialysis and to compare it with normal healthy controls and also to assess the effects of duration of hemodialysis on the lipid profile. Study Design: A case-control study. Setting: Executed in the Nephrology Department of JPMC. Period: January 2018 to January 2019. Material and Methods: Blood samples were obtained from a total of 90 subjects. Subjects were stratified into 3 groups including cases of ESRD receiving maintenance hemodialysis and matched healthy controls. Analysis for serum triglyceride, serum VLDL, total cholesterol, LDL and HDL was done. Results: A significant rise in serum triglyceride content and total serum cholesterol of hemodialysis patients (p < 0.01) was detected as compared to healthy controls. A statistically significant decrease was found in serum HDL level (p < 0.01) in hemodialysis patients in comparison to healthy controls. The impact of the hemodialysis duration was found to deteriorate the lipid profile of patients having longer duration of hemodialysis. Conclusion: Dyslipidemia was found to be evident in hemodialysis patients. The duration of hemodialysis sessions was found to affect the lipid profile of ESRD patients, which may play a role in higher incidence of atherosclerotic related cardiac events among these patients.

P1581IMPACT OF ACHIEVING LDL CHOLESTEROL LOWER THAN 100 MG/DL WITH STATINS, ON LIPID PROFILE AND INFLAMMATION IN END-STAGE RENAL DISEASE PATIENTS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Susana Coimbra ◽  
Flávio Reis ◽  
Sara Nunes ◽  
Sofia D. Viana ◽  
Maria João Valente ◽  
...  
Keyword(s):  
Lipid Profile ◽  
End Stage Renal Disease ◽  
Inflammatory Markers ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Group 2 ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients ◽  
Group 1

Abstract Background and Aims Dyslipidemia is common in chronic kidney disease (CKD) and cardiovascular disease (CVD)-related events are the main causes of death in end-stage renal disease (ESRD) patients on dialysis. Concerning lipid management, clinical practice emphasized treatment escalation to achieve specific low-density lipoprotein cholesterol (LDLc) targets, which implies repeated LDLc evaluations, and enhancement of statin doses or combination of lipid-lowering therapies. However, the LDLc target is not consensual, with some entities suggesting 100 mg/dl and others a more conservative level. It has been hypothesized that lipoprotein’s quality (size, composition and functionality) may be more important than their total circulating levels, as CVD risk factor. Our aim was to evaluate and compare, in ESRD patients on dialysis and under statins treatment, the levels of lipoprotein fractions and subfractions and inflammatory markers, between patients who achieved LDLc levels &lt; 100 mg/dl and those who did not achieve that target. Method We studied 110 ESRD patients on dialysis (high-flux hemodialysis or hemodiafiltration) and under statin therapy; 87 presented a LDLc &lt; 100 mg/dl (group 1) and 23 a value &gt; 100 mg/dl (group 2); levels of high-sensitivity C-reactive protein (hsCRP), interleukin(IL)-6, lipid profile including lipoprotein fractions/subfractions, and oxidized LDL (oxLDL) were evaluated. Results Group 1, as compared to group 2, presented lower values of total cholesterol (TC), triglycerides, oxLDL, TC/high-density lipoprotein cholesterol (HDLc) and LDLc/HDLc ratios. Concerning lipoprotein fractions/subfractions, group 1 presented significantly higher larger and intermediate LDL, and a trend towards lower small LDL (P=0.063), higher large HDL (P=0.069) and lower small HDL (P=0.080); no significant alterations were found for very-low-density lipoprotein and intermediate-density lipoprotein. Regarding inflammatory markers, no significant differences were observed between the 2 groups. Conclusion Patients who achieved the LDLc &lt; 100 mg/dl target presented a better non-conventional lipid profile, including lower oxLDL levels and an increase in larger (less atherogenic) LDL subfractions. According to our data, a lower LDLc level associates with a better lipid profile; the benefits of this improvement on HDL fractions and CVD-related events in ESRD patients on dialysis needs to be better clarified.

Abstract 530: A Cluster of Proteins Implicated in Kidney Disease Are Increased in HDL of Hemodialysis Subjects

2015 ◽  
Vol 35 (suppl_1) ◽  
Author(s):  
Baohai Shao ◽  
Ian de Boer ◽  
Philip S Mayer ◽  
Leila Zelnick ◽  
Maryam Afkarian ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Kidney Disease ◽  
Renal Disease ◽  
Lipoprotein Metabolism ◽  
Density Lipoprotein ◽  
Protein Composition ◽  
Shotgun Proteomics ◽  
Selected Reaction Monitoring ◽  
Stage Renal Disease ◽  
Esrd Patients

Objectives: Cardiovascular disease (CVD) is the leading cause of death in uremic subjects on dialysis. However, this large increase cannot be completely explained by the conventional risk factors frequently seen in this population. One important factor could be alterations of high-density lipoprotein (HDL) protein composition that impair its cardioprotective functions. We therefore investigated alterations in the HDL proteome of end-stage renal disease (ESRD) patients undergoing hemodialysis. Methods and Results: We first used shotgun proteomics to investigate the protein composition of HDL isolated by ultracentrifugation in 20 control and 40 ESRD subjects. This analysis identified 63 proteins in HDL, which were linked to lipid and lipoprotein metabolism, immune response, acute phase response, complement regulation, inhibitors of proteolysis, vitamin binding and transport, and platelet activation/coagulation. We then used targeted proteomics by isotope-dilution MS/MS with selected reaction monitoring (SRM) to provide precise and accurate relative quantification of 37 proteins in HDL. This quantitative approach revealed that 22 proteins (including SAA1, apoA-IV, apoC-II, apoC-III) were significantly enriched and six proteins (including apoA-I, apoA-II, PON1) were significantly decreased in ESRD patients. Moreover, several of these proteins (SAA1, apoC-III, PON1, etc.) have been associated with atherosclerosis. Strikingly, six proteins implicated in renal disease–AMBP, B2M, CFD, CST3, PTGDS and RBP4–were markedly increased in HDL of uremic subjects. Conclusions: Our observations indicate that ESRD markedly remodels the HDL proteome. Moreover, our quantitative analysis of the HDL proteome identified a cluster of six proteins that are dramatically enriched in HDL from patients with ESRD. Our observations support the proposal that the protein cargo of HDL can serve as a marker - and perhaps mediator - of renal disease and serve as novel biomarkers for ESRD status. Therefore, quantifying proteins in HDL might help diagnose and perhaps treat human cardiovascular disease in kidney disease.

scholarly journals The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Susana Coimbra ◽  
Flávio Reis ◽  
Sara Nunes ◽  
Sofia Viana ◽  
Maria João Valente ◽  
...  
Keyword(s):  
End Stage Renal Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Obese Patients ◽  
Cvd Risk Factors ◽  
Cvd Risk ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Cardiovascular disease (CVD) events are the main causes of death in end-stage renal disease (ESRD) patients on dialysis. The number and severity of CVD events remain inappropriate and difficult to explain by considering only the classic CVD risk factors. Our aim was to clarify the changes and the relationship of lipoprotein subfractions with other CVD risk factors, namely, body mass index (BMI) and adipokines, inflammation and low-density lipoprotein (LDL) oxidation, and the burden of the most prevalent comorbidities, diabetes mellitus (DM) and hypertension (HT). We studied 194 ESRD patients on dialysis and 22 controls; lipid profile, including lipoprotein subpopulations and oxidized LDL (oxLDL), C-reactive protein (CRP), adiponectin, leptin, and paraoxonase 1 activity were evaluated. Compared to controls, patients presented significantly lower levels of cholesterol, high-density lipoprotein cholesterol (HDLc), LDLc, oxLDL, and intermediate and small HDL and higher triglycerides, CRP, adiponectin, large HDL, very-low-density lipoprotein (VLDL), and intermediate-density lipoprotein- (IDL) B. Adiponectin levels correlated positively with large HDL and negatively with intermediate and small HDL, oxLDL/LDLc, and BMI; patients with DM (n=17) and with DM+HT (n=70), as compared to patients without DM or HT (n=69) or only with HT (n=38), presented significantly higher oxLDL, oxLDL/LDLc, and leptin and lower adiponectin. Obese patients (n=45), as compared to normoponderal patients (n=81), showed lower HDLc, adiponectin, and large HDL and significantly higher leptin, VLDL, and intermediate and small HDL. In ESRD, the higher adiponectin seems to favor atheroprotective HDL modifications and protect LDL particles from oxidative atherogenic changes. However, in diabetic and obese patients, adiponectin presents the lowest values, oxLDL/LDLc present the highest ones, and the HDL profile is the more atherogenic. Our data suggest that the coexistence of DM and adiposity in ESRD patients on dialysis contributes to a higher CVD risk, as showed by their lipid and adipokine profiles.

scholarly journals Evaluation of dyslipidemia in type 2 diabetes mellitus

2015 ◽  
Vol 6 (6) ◽  
pp. 16-19 ◽  
Author(s):  
Devendra Pratap Singh Rajput ◽  
Javed Yusuf Shah ◽  
Priti Singh ◽  
Shyransh Jain
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Lipid Profile ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Serum Triglyceride ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients

Back ground: In type 2 diabetes mellitus lipid abnormalities are almost the rule. Dyslipidemia has been noted to play an integral role in the pathogenesis and progression of micro and macrovascular complications in diabetes mellitus patients. The complications exemplified by renal, cerebrovascular and cardiovascular disease cause the most morbidity and mortality in this group of patients.Aims and Objectives: This study is aimed at understanding the pattern of dyslipidemia among type 2 diabetic patients. Materials and Methods: During two month study period, total 100 patients with diabetes mellitus were evaluated for dyslipidemia. Plasma glucose was estimated by GOD –POD method and Lipid profile by photometry method. Lipid profile was evaluated by investigating the subjects for total cholesterol, serum triglyceride, high density lipoprotein, low density lipoprotein and very low density lipoprotein. In statistical analysis data were analyzed by using various statistical methods like percentage, proportions and tables by using epi info software.Results: Out of 100 patients 72(72%) were males and 28(28%) were females. The mean  fasting blood sugar of total patients with type 2 diabetes mellitus was 158.35mg/dl. in male diabetics, fasting blood sugar level with diabetes mellitus was 157.56mg/dl and in female diabetics it was 159.14mg/dl. The pattern of dyslipidemia in our study showed significantly higher levels of serum cholesterol, serum triglyceride, LDL-C in both male and female diabetics and lower levels of HDL-C in female diabetics. There was no significant difference in lipid profile pattern in male and female diabetic patients except lower levels of HDL-C in female diabetic patients. Conclusion: This study showed that dyslipidemia is highly prevalent among type 2 diabetic patients. DOI: http://dx.doi.org/10.3126/ajms.v6i6.12452Asian Journal of Medical Sciences Vol.6(6) 2015 16-19                                     

scholarly journals Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease

2002 ◽  
Vol 62 (6) ◽  
pp. 2230-2237 ◽  
Author(s):  
Tetsuo Shoji ◽  
Mariko Fukumoto ◽  
Eiji Kimoto ◽  
Kayo Shinohara ◽  
Masanori Emoto ◽  
...  
Keyword(s):  
Renal Disease ◽  
Cardiovascular Mortality ◽  
End Stage Renal Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Oxidized Low Density Lipoprotein ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Study of Lipid profile in a population of university students

2013 ◽  
Vol 21 (5) ◽  
pp. 1151-1158 ◽  
Author(s):  
Roberto Wagner Junior Freire de Freitas ◽  
Marcio Flavio Moura de Araujo ◽  
Adman Camara Soares Lima ◽  
Dayse Christina Rodrigues Pereira ◽  
Ana Maria Parente Garcia Alencar ◽  
...  
Keyword(s):  
University Students ◽  
Lipid Profile ◽  
Clinical Laboratory ◽  
Demographic Data ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Cross Sectional Study ◽  
Blood Collection ◽  
Young Population ◽  
Cross Sectional

OBJECTIVE: to evaluate the lipid profile in a population of university students. METHODS: cross-sectional study with 702 students, of both genders enrolled in various courses at a public university in Fortaleza-CE. The demographic data and data on lifestyle habits were collected through a self-administered questionnaire. The blood collection was performed in a clinical laboratory. RESULTS: showed a predominantly young population, with a mean age of 21.5 years with more females (62.7%). High levels of triglycerides, total cholesterol and cholesterol associated with low density lipoprotein (LDL-c) were found in 23.0%, 9.7% and 5.9% of students, respectively. The cholesterol associated with high density lipoprotein (HDL-c) was at reduced values in 12.0% of subjects and was significantly associated with smoking (p=0.0231) and physical inactivity (p=0.0357). CONCLUSION: changes in lipid profile are present in the young population and intervention studies should be encouraged in order to reduce the prevalence of cardiovascular disease in adulthood.

scholarly journals Atorvastatin and carnitine combination versus atorvastatin alone impacts on the lipid profile of haemodialyzed patients: A randomised clinical trial

2018 ◽  
Vol 6 (4) ◽  
pp. 165-171
Author(s):  
Hamid Noshad ◽  
Davoud Mohammadi Nejhad ◽  
Parastou Hoseini ◽  
Majid Montazer ◽  
Behnaz Ghamari ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Lipid Profile ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Randomised Clinical Trial ◽  
Hemodialysis Patients ◽  
The Other ◽  
Medical Sciences ◽  
Before And After

Introduction: Dyslipidemia is one of the most common problems in hemodialysis patients and healthcare system. Some studies have suggested the use of carnitine in the treatment of dyslipidemia in hemodialysis patients. This study was carried out aiming to evaluate the effect of atorvastatin and carnitine combination versus atorvastatin alone on the lipid profile of hemodialyzed patients. Methods: In this clinical trial, 50 hemodialysis patients referred to the educational centres of Tabriz University of Medical Sciences, Tabriz, Iran, for haemodialysis were enrolled. Patients were randomly assigned into two groups. In the first group, patients were treated with carnitine (1000 mg three times daily) and atorvastatin (10-80 mg/day based on the baseline lipid profile of the patients) and in the second group, the patients were treated with atorvastatin alone for six months. The levels of triglyceride (TG), cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and haemoglobin before and after intervention were compared. The side effects of carnitine administration were also evaluated. Results: Results showed that TG, cholesterol, and LDL levels were significantly lower in the carnitine group compared to those in the other group at the end of study (P < 0.050). In addition, HDL and haemoglobin levels were significantly higher in the carnitine group in comparison to the other group (P < 0.050). No major side effects of carnitine were observed among the patients. Conclusion: The use of carnitine plus atorvastatin combination is an effective and safe method in the treatment of dyslipidemia in patients undergoing hemodialysis without imposing significant side effects.

Sign in / Sign up

Export Citation Format

Share Document